SCHEMBL2934045

SCHEMBL2934045

O=C(NCc1ccc(Cl)cc1)c1cc(CN2CC(=O)N(c3ccc(OC(F)(F)F)cc3)C2=O)ccn1

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP2C9 P11712 5/20 0.42
CYP3A4 P08684 1/20 0.42
ABCB1 P08183 1/20 0.41
MMP13 P45452 1/20 0.40
PPARD Q03181 2/20 0.40
PPARA Q07869 2/20 0.40
PPARG P37231 1/20 0.40
MEN1 O00255 1/20 0.40
KMT2A Q03164 1/20 0.40
EPHX2 P34913 1/20 0.39
NR1H4 Q96RI1 1/20 0.39
METAP2 P50579 1/20 0.39
HPGD P15428 4/20 0.39
CYP1A2 P05177 3/20 0.39
CYP2C19 P33261 3/20 0.39
NPSR1 Q6W5P4 1/20 0.39
ALDH1A1 P00352 3/20 0.39
CYP2D6 P10635 2/20 0.39
SMN1; SMN2 Q16637 2/20 0.39
ADRB2 P07550 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2938007 0.92 ALDH1A1 (0.44) CYP2C9CYP3A4MMP13PPARDPPARA
SCHEMBL2940764 0.87 IGF1R (0.53) MMP13IGF1R
SCHEMBL2942073 0.86 MMP13 (0.40) CYP2C9MMP13PPARDPPARAPPARG
SCHEMBL2933018 0.86 IGF1R (0.50) PPARDPPARAPPARGEPHX2ALDH1A1
SCHEMBL2939649 0.84 ABL1 (0.46) PPARDPPARAPPARGMEN1KMT2A
SCHEMBL2941245 0.84 GCGR (0.52) CYP2C9CYP3A4ABCB1MMP13METAP2
SCHEMBL2937368 0.84 GCGR (0.43) PPARDPPARAPPARGGCGR
SCHEMBL2935376 0.84 PPARD (0.48) PPARDPPARAPPARGEPHX2ALDH1A1
SCHEMBL2934887 0.84 IGF1R (0.47) PPARDPPARAPPARGALDH1A1SMN1; SMN2
SCHEMBL2932880 0.83 IGF1R (0.59) IGF1RGCGR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7825115-B2 Cyclic urea compounds, preparation thereof and pharmaceutical use thereof as kinase inhibitors AVENTIS PHARMA S.A. (FR) 2010-11-02 US disclosed
EP-1599464-B1 NOVEL CYCLIC UREA DERIVATIVES, PREPARATION METHOD THEREOF AND PHARMACEUTICAL USE OF SAME AS KINASE INHIBITORS AVENTIS PHARMA SA (FR) 2010-09-22 EP disclosed
US-20080108654-A1 Cyclic Urea Compounds, Preparation Thereof and Pharmaceutical Use Thereof as Kinase Inhibitors AVENTIS PHARMA S.A. (FR) 2008-05-08 US disclosed
US-7354933-B2 Protein kinase inhibitors; antitumor agents; such as 5-methyl-1-quinol-4-ylmethyl-3-(4-trifluoromethanesulfonylphenyl)imidazolidine-2,4-dione trifluoroacetate AVENTIS PHARMA SA (FR) 2008-04-08 US disclosed
US-20040248884-A1 Novel cyclic urea derivatives, preparation thereof and pharmaceutical use thereof as kinase inhibitors AVENTIS PHARMA S.A. (FR) 2004-12-09 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080108654-A1 Cyclic Urea Compounds, Preparation Thereof and Pharmaceutical Use Thereof as Kinase Inhibitors PRKG1, PRKACA, CMPK1 CYP2C9 2056/4885CYP3A4 2988/4885ABCB1 1794/4885
US-20040248884-A1 Novel cyclic urea derivatives, preparation thereof and pharmaceutical use thereof as kinase inhibitors PRKG1, PRKACA, PRKCA CYP2C9 2119/4885CYP3A4 2877/4885ABCB1 1621/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.